Tenet Healthcare (THC) shares soared 7.7% in the last trading session to close at $89.11. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 11.5% gain over the past four weeks.The stock price surge can be linked to a piece of upbeat company news, revealing that it expects to surpass the upper limit in its 2023 adjusted EBITDA guidance range. This positive outlook is attributed to robust surgical growth in USPI operations. Concurren ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Tenet Healthcare (THC) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Februar ...

Acquisition of Tenet's Pacific Coast Network would expand unrestricted to healthcare for Orange County and beyond ORANGE, Calif., Feb. 1, 2024 /PRNewswire/ -- The Regents of the University of California, on behalf of the University of California, Irvine, has entered into a definitive agreement with Tenet Healthcare Corporation (NYSE: THC) to acquire Tenet's Pacific Coast Network. The network will become part of UCI Health, the clinical enterprise of UC Irvine.   "UC Irvine has deepened its healthcare commit ...

Acquisition of hospitals in Charleston, Hardeeville and Hilton Head extends Novant Health's presence into South Carolina WINSTON-SALEM, N.C., Feb. 1, 2024 /PRNewswire/ -- Novant Health is building upon its commitment to patients in South Carolina through its completed acquisition today of three coastal hospitals and associated physician clinics and operations from Tenet Healthcare Corporation (NYSE: THC). The transaction includes East Cooper Medical Center in Mount Pleasant, Hilton Head Hospital in Hilton H ...

Tenet Healthcare (THC) closed the latest trading day at $83.57, indicating a +0.82% change from the previous session's end. This move outpaced the S&P 500's daily gain of 0.76%. Elsewhere, the Dow saw an upswing of 0.59%, while the tech-heavy Nasdaq appreciated by 1.12%.The hospital operator's stock has climbed by 9.69% in the past month, exceeding the Medical sector's gain of 1.57% and the S&P 500's gain of 2.5%.The investment community will be closely monitoring the performance of Tenet Healthcare in its ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Tenet Healthcare (THC) . This company, which is in the Zacks Medical - Hospital industry, shows potential for another earnings beat.This hospital operator has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 17.14%.For the ...

DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) will release its fourth quarter 2023 results on Thursday, February 8, 2024, no later than 6:00 a.m. Central Time (CT), to be followed by a conference call at 9:00 a.m. CT (10:00 a.m. Eastern Time). A live webcast and audio archive of the call may be accessed through the investor relations section of Tenet’s website at www.tenethealth.com/investors. About Tenet Healthcare Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare ...

Financial Data and Key Metrics Changes - In Q3 2023, the company generated net operating revenues of $5.1 billion and consolidated adjusted EBITDA of $854 million, resulting in an attractive margin of almost 17% [6][28] - Adjusted EBITDA for USPI grew 16% compared to Q3 2022, with adjusted EBITDA margins remaining strong at 39.3% [29][30] - Consolidated SW&B costs as a percentage of revenue were 45.2%, down from 46.4% in Q3 2022 [37] Business Line Data and Key Metrics Changes - USPI reported $370 million of adjusted EBITDA, a 16% increase year-over-year, with same-facility revenues growing by 7.9% [7][29] - The Hospital segment generated $401 million of adjusted EBITDA, with revenue per adjusted admission increasing by 3.2% compared to Q3 2022 [11] - Conifer's third-quarter adjusted EBITDA was $83 million, with a strong margin of 26.3% [39] Market Data and Key Metrics Changes - Same-store inpatient admissions increased by 4.5% on a non-COVID basis, while same-hospital inpatient admissions rose by 0.6% compared to the previous year [36] - Year-to-date, non-COVID admissions are up 7.6% over last year [36] Company Strategy and Development Direction - The company remains focused on attracting high-quality physicians and expanding its portfolio, adding six new centers during the quarter, primarily in higher-acuity orthopedic services [9][10] - The strategic focus is on higher-acuity services, which are expected to provide better margins and stronger cost management capabilities [38] - The company is committed to scaling its USPI business and has a robust acquisition pipeline with attractive opportunities [9][10] Management's Comments on Operating Environment and Future Outlook - Management raised the full-year 2023 adjusted EBITDA guidance to a range of $3.365 billion to $3.465 billion, reflecting strong performance [25] - The company anticipates some increases in costs due to rising patient demand but remains disciplined in managing contract labor and overall expenses [15][17] - Management expressed confidence in the ongoing recovery of healthcare services and the ability to deliver on increased guidance for 2023 [48] Other Important Information - The company has over $1 billion in cash on hand and no significant debt maturities until 2026, providing financial flexibility [32][27] - The company has successfully settled over 30 labor union contract negotiations in the past two years, balancing employee needs with cost structure [18] Q&A Session Summary Question: Clarification on earnings growth for 2024 - Management confirmed that they are assuming EBITDA growth in 2024 compared to 2023, despite headwinds from reduced government funding and new regulations [52][54] Question: ASC segment growth and pricing - Management noted that while there may be moderation in growth rates, the ASC segment continues to perform well above long-term projections [55] Question: Revised guidance and fourth-quarter performance - Management indicated that they are not seeing anything different in Q4 performance at this stage, but are cautious due to potential COVID spikes [60][62] Question: Managed care contracting for 2024 and 2025 - Management expects mid-single-digit commercial rate increases, reflecting the current inflationary environment [87] Question: Labor environment and minimum wage impacts - Management acknowledged the challenges posed by the California minimum wage increase but believes it will be manageable [91] Question: Capacity additions and growth opportunities - Management stated that they have maintained or slightly increased capacity this year, focusing on high-demand service lines [95] Question: Professional fee expenses for 2023 - Medical fee costs are up around 15% compared to last year, consistent with expectations [106] Question: Growth in USPI specialties - Management reported that hips and knees surgeries grew in the mid-teens year-over-year, with strong performance in other specialties like GI and ENT [110]

Cautionary Statements NON-GAAP FINANCIAL INFORMATION Conifer • 4.1% case volume growth FY 2023 Outlook - Consolidated Adjusted EBITDA raised for the third time this year to a range of $3.365 billion to $3.465 billion 4 Note: 2023E is based on mid-point of Outlook range as of October 30, 2023. Reconciliations of these non-GAAP measures to the most comparable GAAP measures and management's reasoning for using these non-GAAP financial measures are included in our earnings press releases dated October 30, 2023, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ý Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2023 OR Form 10-Q TENET HEALTHCARE CORPORATION (Exact name of Registrant as specified in its charter) Nevada (State of Incorporation) 95-2557091 (IRS Employer Identification No.) 14201 Dallas Parkway Dallas, TX 75254 (Address of principal executive offices, including zip code) (469) 893-2200 (Registrant's ...